The proposal addresses a molecular gap between established links. Long-term rotating-shift work is associated in meta-analyses with a 20%–40% excess risk of coronary heart disease and incident heart failure after adjustment for smoking, obesity and hypertension, while chronic phase shifts and forced rest-phase activity can produce cardiac hypertrophy or fibrosis in rodents. Cardiomyocytes also operate an intrinsic molecular clock: BMAL1 and CLOCK activate genes involved in timing metabolism, contractile-protein turnover and stress responses, and an estimated 8%–13% of the cardiac transcriptome varies over the course of a day. Deleting Bmal1 specifically in cardiomyocytes causes age-dependent dilated cardiomyopathy in mice, making genetic clock loss a powerful model for studying the underlying biology.

Growth hormone is a plausible bridge between timing and cardiac disease. About 70% of daily growth hormone release in humans occurs during early nocturnal sleep, but its pulse amplitude, timing and trough concentrations can change with circadian misalignment. Cardiomyocytes express functional growth hormone receptors, which signal through JAK2, STAT5, PI3K–AKT and MAPK–ERK pathways involved in cardiac growth, metabolism and fibrosis. The review’s central hypothesis is that the cardiomyocyte clock acts as a temporal filter: it may restrict receptor availability or downstream responsiveness during phases when growth hormone would otherwise provoke an unhelpful response. Circadian misalignment could remove or blur that restraint, allowing mistimed growth hormone pulses to engage remodeling programs.

Direct cardiac evidence comes from the cardiomyocyte-specific Bmal1 knockout model, or CBK mice. Compared with floxed controls, these animals exhibited approximately twice as much cardiac Igf1 messenger RNA and stronger STAT5 phosphorylation after an injected growth hormone challenge. The same hearts also showed activation of phosphorylated ERK, mTOR and 4EBP1. This response was cardiac-specific: livers from the same animals did not display a corresponding increase, suggesting that the local cardiomyocyte clock limits growth hormone responsiveness rather than merely reflecting a systemic change. In a separate causal test, deleting one Ghr allele normalized cardiac Igf1 expression and partially reduced hypertrophy and the progression of fibrosis in CBK mice.

That rescue is important but requires careful interpretation. Global Ghr haploinsufficiency cannot show that growth hormone receptors in cardiomyocytes alone caused the benefit, because reducing receptor gene dosage could also alter systemic growth hormone and circulating IGF-1. The partial rescue further indicates that other pathways contribute to clock-related cardiac damage. The downstream measurements also leave ambiguity: elevated Igf1 supports local production through GHR–JAK2–STAT5 signaling, but some PI3K–AKT and mTOR activity could arise from IGF-1 acting on IGF-1 receptors or hybrid receptors. Cardiac-specific Igf1r deletion or receptor blockade would be needed to separate these routes. Moreover, a larger response to an injected growth hormone pulse is not the same as continuous signaling without stimulation, because basal STAT5 phosphorylation was not measured across the day.

The proposed molecular restraint is led by REV-ERBα, a clock-controlled transcriptional repressor. The authors suggest that REV-ERBα may periodically suppress Ghr, Stat5a or Stat5b, while SOCS2 could provide a second, rhythmically timed negative-feedback brake. Hepatic studies provide a precedent: liver growth hormone receptor expression, JAK2 abundance and growth hormone-induced STAT5 activity vary by time of day, and hepatic SOCS2 follows growth hormone pulse timing. Nevertheless, no direct cardiomyocyte evidence yet shows REV-ERBα binding at the relevant cardiac gene promoters, and the idea that the cardiac Socs2 promoter contains functional ROR response elements has not been tested in any tissue. The precise chromatin mechanism therefore remains inferred rather than demonstrated.

Environmental disruption models expose a major gap between genetic clock loss and realistic misalignment. CBK mice have their cardiomyocyte clock abolished, potentially providing a ceiling estimate of how much clock perturbation can affect growth hormone signaling. By contrast, shift work, social jet lag and chronic sleep disturbance change the phase, amplitude or synchrony of oscillations without necessarily eliminating them. Chronic weekly 12-hour phase reversals have produced cardiomyopathy in hamsters and mice, while five weeks of enforced wakefulness during the rest phase reprogrammed a rat cardiac transcriptome, increased extracellular-matrix and inflammatory genes and caused fibrosis. Neither model measured cardiac growth hormone or IGF-1 pathway activity. Human forced-desynchrony studies have found blunted nocturnal growth hormone surges, redistributed pulses and elevated troughs, but cardiac pathway measurements in environmentally disrupted humans are unavailable.

Several pharmacological strategies follow from the hypothesis, but none has yet been validated as a treatment for circadian cardiomyopathy. Somatostatin analogues such as octreotide and lanreotide suppress pituitary growth hormone release; in acromegaly, six to 12 months of biochemical control is associated with a 5%–15% reduction in left-ventricular mass index and improved diastolic function. Their weakness in a timing disorder is that they suppress pulses without distinguishing ectopic release from physiological nocturnal secretion. Pegvisomant, a pegylated growth hormone receptor antagonist, instead blocks signaling regardless of pulse timing and normalizes serum IGF-1 in roughly 90% of acromegaly patients at reported doses of 10–30 mg per day. Whether it can prevent remodeling after chronic jet lag remains an untested preclinical question, and transaminase elevations occur in about 5%–10% of treated patients.

Clock-targeted compounds offer another experimental approach. The REV-ERB agonists SR9009 and SR9011 enhance recruitment of the NCoR/HDAC3 corepressor complex and could, under the proposed model, restore repression of growth hormone pathway genes. SR9009 has reduced fibrosis and improved function in a mouse pressure-overload model, but that study did not measure growth hormone signaling, the compound has poor oral bioavailability and a plasma half-life below one hour in mice, and it retains metabolic effects in cells lacking REV-ERBα/β. Nobiletin can enhance circadian amplitude in rodent models, while CRY stabilizers such as KL001 extend the negative feedback phase of the clock. Neither class has convincing cardiac data for this pathway, and lengthening the clock period could worsen desynchrony between the heart and central clock. A combined clock-stabilizing and growth hormone-modulating treatment is therefore a testable concept without supporting preclinical efficacy data.

The review also places the proposed growth hormone axis alongside better-established alternatives. A chronic jet-lag model in mice produced an HFpEF-like combination of hypertrophy, fibrosis and diastolic dysfunction while reducing Clock-dependent soluble guanylate cyclase expression and cGMP–PKG1 signaling; the sGC stimulator riociguat attenuated the structural changes. Inflammation, altered fuel use and loss of nocturnal blood-pressure dipping are also recognized candidates. Growth hormone–STAT5 and sGC–cGMP–PKG1 pathways may converge on shared hypertrophic and fibrotic genes, but their relative importance is unresolved. Priority experiments include measuring cardiac STAT5 phosphorylation across multiple day times during chronic jet lag, testing pegvisomant against vehicle in disrupted animals, determining whether SR9009 acts through REV-ERBα, and separately manipulating cardiac IGF-1 receptors. Most direct evidence currently comes from one laboratory and one genetic mouse model, and the differences between rodent and human growth hormone physiology require independent replication. If controlled experiments confirm that misalignment amplifies cardiac growth hormone responsiveness, targeted restoration of timing or selective suppression of excess signaling could become a component of future circadian-cardiomyopathy therapy; at present, that possibility remains an experimental direction rather than a clinically established intervention.

Subject of Research: Circadian control of cardiac growth hormone signaling and cardiomyopathy

Article Title: Augmented cardiac growth hormone signaling in circadian-disrupted cardiomyopathy

Article References: Ibrahim, D., & Sonkar, R. (2026). Augmented cardiac growth hormone signaling in circadian-disrupted cardiomyopathy. Frontiers in Pharmacology, 17, Article 1982446. https://doi.org/10.3389/fphar.2026.1982446

Image Credits: AI Generated

DOI: 10.3389/fphar.2026.1982446

Keywords: cardiac hypertrophy, cardiomyopathy, chronopharmacology, circadian clock, growth hormone, Bmal1, REV-ERBα, STAT5, IGF-1, shift work, Augmented, cardiac

Central precocious puberty, which results from early activation of the hypothalamic-pituitary-gonadal axis, provides the largest focus of the collection. In one study, Liu and colleagues analysed polymorphisms in the estrogen receptor beta, or ERβ, gene in girls with idiopathic central precocious puberty. Certain polymorphisms, described primarily as the ERβ RsaI and Rraa haplotypes, appeared to be associated with an increased risk of the disorder.

The authors suggested that these variants may serve as prognostic or risk factors, but the editorial presents them as associations requiring further investigation rather than as established clinical tests. Research on circulating microRNAs offered another possible route into the biology of early puberty. Morrou and colleagues compared girls with central precocious puberty and healthy controls and reported differential expression of microRNA pathways.

In particular, miR-148a-3p was markedly increased in extracellular vesicles in the affected group. Because the increase concerned pathways associated with a neurological condition, the result supported a hypothesis that post-transcriptional regulation may help explain the early activation of the hypothalamic-pituitary-gonadal axis. The investigators also described the work as groundwork for identifying minimally invasive biomarkers, a step that does not amount to clinical validation.

Environmental factors form another strand of the collection. Nie and colleagues used computational analyses to examine bisphenol A, a substance widely used in plastic manufacturing, and identify potential molecular targets associated with precocious puberty. This was a computational study and did not demonstrate that bisphenol A exposure causes precocious puberty in children.

A mini-review by Amodeo and colleagues separately brought together the genetic and environmental causes of peripheral precocious puberty in males. The editorial also notes that many centres, including the editors’ own, reported a significant increase in central precocious puberty cases during the COVID-19 pandemic, when environmental pressure was greatest. That observation provides clinical context but does not identify why the increase occurred.

The relationship between metabolism and diagnosis was examined in a study of 1,077 premenarcheal girls with idiopathic central precocious puberty. Yuan and colleagues found that body mass index correlated with basal luteinising hormone, or LH, and with other markers of pubertal development. These findings align with the editorial’s emphasis on assessing patients beyond isolated biochemical values and considering a broader range of factors.

The research is especially relevant to the use of basal LH as a marker of hypothalamic-pituitary-gonadal-axis activation. The editors also connect this approach with the Endocrine Society’s 2026 guidelines, which they describe as favouring an integrated assessment rather than one limited to biochemistry. Puberty also creates an opportunity to evaluate adrenal function.

Zhang and colleagues studied adolescent girls with polycystic ovary syndrome using liquid chromatography coupled with tandem mass spectrometry. The researchers documented multiple alterations in androgen metabolic pathways in this population and reported that the free androgen index was particularly effective for diagnosis, in line with other studies. The work provides information about metabolic profiling and diagnostic performance in a defined group of adolescent girls.

It does not report a treatment, nor does it establish that any of the observed pathway changes causes polycystic ovary syndrome. Longitudinal development became the focus in a retrospective cohort of 171 children examined by Gürlek and colleagues. The study considered familial, constitutional and combined forms of idiopathic short stature and found that children with these diagnoses did not necessarily follow the same developmental course.

Pubertal timing was important when interpreting growth over time, and some children experienced spontaneous improvement, particularly after puberty. The authors therefore advocated a longitudinal growth assessment before starting recombinant growth hormone therapy, using a broad range of parameters rather than a single initial measurement. Recombinant GH has a favourable overall safety profile, but its systemic growth-promoting effects require appropriate clinical surveillance.

Two contributions addressed the heart during childhood endocrine treatment. Ruiz del Olmo-Izuzquiza and colleagues prospectively assessed cardiac morphology, function and aerobic performance. Although an increase in left ventricular mass was expected, the researchers observed physiological cardiac remodeling rather than pathological hypertrophy.

Systolic function remained preserved, and the study also recorded early subclinical improvements in cardiac contractility. A separate review by Li and Wang examined systemic glucocorticoid exposure during childhood and its effects on myocardial structure and function. Evidence broken down by age group remains limited.

Available findings suggest that structural changes most often manifest as treatment-reversible myocardial hypertrophy, while evidence for permanent structural damage remains insufficient. The collection also includes an effort to make follow-up more individualized. Ly and colleagues applied interpretable predictive models to boys receiving growth hormone therapy.

Current IGF-1 SDS was the strongest predictor of subsequent IGF-1 levels, while treatment-related and puberty-related variables provided additional predictive information. The model identifies statistical relationships within the studied group rather than guaranteeing an individual response or replacing clinical assessment. In a separate contribution, Zhang and colleagues described a patient with P450 oxidoreductase deficiency carrying a previously unreported POR variant.

By combining the case with a systematic review of 167 reported patients, the study illustrated the diagnostic value of integrating endocrine phenotyping with molecular genetics. Taken together, the studies portray growth and pubertal development as processes that cannot be captured adequately through a single hormone value, genetic marker or physical measurement. The reported findings cover central precocious puberty, peripheral precocious puberty, adolescent adrenal metabolism, idiopathic short stature, growth-hormone treatment, steroid exposure, cardiac safety, predictive modelling and a rare disorder of steroidogenesis.

Their scope varies from individual case reports and computational work to retrospective and prospective cohorts, each with its own population and limitations. The editors conclude that the issue provides new evidence and useful questions for paediatric endocrinologists, while explicitly calling for further investigation and larger validation samples as the field works through the clinical challenges surrounding growth and puberty.

Subject of Research: Research on genetic, environmental, metabolic and clinical influences on paediatric growth and pubertal development.

Article Title: Editorial: Growth and pubertal development in paediatric endocrinology: from physiological pathways to clinical challenges

Article References: Candela, E., Zucchini, S., & Baronio, F. (2026). Editorial: Growth and pubertal development in paediatric endocrinology: from physiological pathways to clinical challenges. Frontiers in Pediatrics, 14, Article 2020433. https://doi.org/10.3389/fped.2026.2020433

Image Credits: AI Generated

DOI: 10.3389/fped.2026.2020433

Keywords: paediatric endocrinology, puberty timing, central precocious puberty, growth hormone therapy, IGF-1, bisphenol A, polycystic ovary syndrome, idiopathic short stature, microRNAs, P450 oxidoreductase deficiency, Editorial, Growth

Correct dosing of growth hormone in children with or without classic GH deficiency can be challenging. Even after receiving treatment for several years, a significant percentage of patients fail to achieve target height based on parental heights, indicating that the effectiveness of treatment varies among individuals. GH dosing therefore requires individualized assessment and ongoing monitoring to optimize growth outcomes while minimizing risks. IGF-1-based dosing, where the GH dose is titrated to achieve a desired IGF-1 standard deviation score, has been proposed as a strategy for personalizing treatment. However, despite its widespread use in clinical practice, the predictors of IGF-1 levels during later stages of GH therapy remain incompletely understood, particularly during the maintenance phase and puberty where IGF-1 dynamics become more complex.

IGF-1 levels are influenced by multiple physiological and treatment-related factors. In GH-naïve individuals, age and sex are known determinants, with IGF-1 levels increasing throughout childhood and reaching a peak during puberty. In prepubertal children, IGF-1 is associated with height velocity, whereas during puberty, IGF-1 levels may remain elevated despite declining growth velocity. Following the initiation of GH therapy, an initial catch-up phase characterized by rapid growth is typically followed by a maintenance phase and subsequently a pubertal growth spurt. During the early phase of treatment, IGF-1 appears to be positively correlated with GH dose. In one of the few trials employing IGF-1-based dosing, higher GH doses were needed to maintain IGF-1 levels at the higher end of the normal range. Conversely, some studies did not show any significant association between IGF-1 z-scores and GH dose in their cohorts of prepubertal children on GH when adjusted for age, gender, race and insurance type. During maintenance and pubertal growth, the dose dependency is not as obvious, implying that other factors become more impactful at later treatment stages.

Most existing prediction models in pediatric GH therapy have focused on growth outcomes and have relied on multiple linear regression or empirical curve fitting approaches. More recently, machine learning methods have been applied to predict growth outcomes or treatment adherence, while prediction of IGF-1 levels has received less attention. Furthermore, while a model designed to predict growth response may maximize growth outcomes, it does not account for safety. This aspect of treatment can be addressed by focusing on IGF-1 as the predictive target. In non-GH-treated populations, both low and high IGF-1 levels are linked to mortality risk, underscoring the need for IGF-1 regulation in GH treatment. Machine learning approaches are well suited to identifying complex and potentially non-linear relationships between clinical variables, but in healthcare settings it is important that clinicians are able to follow the model’s reasoning and evaluate the resulting recommendation, which is possible in so-called white-box models.

In this study, the researchers applied three interpretable modeling approaches with good performance in small datasets: linear regression, Elastic Net regression, and explainable boosting machine (EBM). Linear regression was used as a baseline method representing standard statistical analysis. Elastic Net regression combines L1 and L2 regularization to improve model stability and variable selection, particularly when multiple predictors are correlated. EBM is a tree-based gradient-boosting method designed to balance flexibility and interpretability. These approaches allow detailed examination of how individual predictors contribute to IGF-1 levels in complex datasets. The study population originated from a larger cohort of 153 short-statured children who participated in the Catch-up growth study, of whom 98 children who achieved catch-up growth were included in a subsequent randomized, prospective, open-label clinical trial conducted in Sweden. Of the 98 participants, the present analysis was restricted to the 72 boys; the 26 girls were excluded because sex-related differences in hormonal regulation and growth patterns precluded combined modeling. Twenty-two boys had GH deficiency, defined as a peak GH concentration below 10 µg/L on both the arginine-insulin tolerance test and a 24-hour spontaneous GH profile, whereas the remaining 50 had idiopathic short stature.

The selected variables were based on previously identified predictors of growth and were categorized into three groups: early-life variables, variables related to the initiation of GH treatment, and variables corresponding to the time of prediction. Early growth data were obtained from child welfare centers, and additional clinical data including height, weight, testicular volume, IGF-1 levels, IGF-binding protein-3, and GH dose were collected at least annually and every three months during active participation in the Maintenance study. After applying the prespecified eligibility criteria and requiring complete data for the outcome and the common set of 33 candidate predictors, 62 boys contributed 165 observation pairs to the 3-month analysis and 65 boys contributed 306 observation pairs to the 12-month analysis. Hormone analyses were conducted at the Gothenburg Pediatric Growth Research Centre Laboratory, with estradiol and testosterone analyzed using validated high-sensitivity gas chromatography-tandem mass spectrometry and serum IGF-1 and IGFBP3 concentrations analyzed using a specific radioimmunoassay.

Model performance was evaluated using nested cross-validation with patient-level grouping. Participants were assigned to five reproducible outer folds, with all observations from a participant assigned to the same outer fold. In each outer iteration, models were developed using four folds and evaluated on the remaining fold, so that every eligible observation received one out-of-fold prediction from a model that had not been trained or tuned using that participant. Hyperparameter selection was performed only within the corresponding outer training data using three-fold patient-grouped inner cross-validation. Patient-balanced performance estimates were calculated from the pooled out-of-fold predictions, with each participant contributing equal total weight irrespective of the number of observations. Uncertainty was quantified using 2,000 patient-cluster bootstrap resamples, and performance estimates were reported with 95% confidence intervals.

The results showed that Elastic Net had the highest point estimates at 3 months, with an R-squared of 0.57 compared with 0.50 for full linear regression and 0.52 for EBM, but confidence intervals did not establish a difference between the primary models. No clear differences between models were found at 12 months, where R-squared values ranged from 0.41 to 0.45. As a reference, a persistence model using current IGF-1 SDS as the prediction of future IGF-1 SDS showed lower predictive performance than the multivariable models at both prediction intervals. Elastic Net identified five consistently selected predictive features at both prediction horizons, defined as predictors with non-zero coefficients across all five outer cross-validation models. For the 3-month prediction, these were IGF-1 SDS at prediction, IGF-1 increase, GH dose, testicular volume, and age at GH treatment start. For the 12-month prediction, the consistently selected features were IGF-1 SDS at prediction, testosterone decrease, testicular volume, age at prediction, and IGF-1/IGFBP-3 increase. IGF-1 SDS at prediction showed the largest median coefficient at both prediction horizons. In the EBM analysis, IGF-1 SDS at prediction showed the highest median main-effect importance at both prediction horizons.

The comparatively lower performance of ordinary linear regression may partly reflect the limitations of applying an unregularized linear model in a dataset with many potentially correlated predictors. Elastic Net may improve predictive performance in this setting by applying regularization and variable selection, thereby reducing the risk of overfitting. EBM provided a complementary assessment of predictive feature importance, although its greater flexibility did not result in clearly improved predictive performance compared with Elastic Net. GH dose received a non-zero Elastic Net coefficient in all five outer-fold models for the 3-month prediction and was also among the features with the highest median importance in the EBM analysis, supporting its relevance for short-term prediction of IGF-1 SDS. This is consistent with previous studies showing an association between GH dose and IGF-1 levels, although the strength of this relationship may vary across treatment phases and patient populations. Puberty-related variables contributed particularly to the 12-month prediction, with testicular volume consistently selected by Elastic Net at both prediction horizons, while age at prediction and testosterone decrease also received non-zero coefficients in all five outer-fold models at 12 months. These findings support the relevance of pubertal development for IGF-1 dynamics during longer prediction intervals, though interpretation of IGF-1 SDS during puberty is challenging, as pubertal development and sex steroid levels are not fully accounted for by age-based reference values.

Despite the relatively small cohort, the prospective longitudinal design, repeated measurements, and limited missing data allowed investigation of IGF-1 dynamics over several years of treatment. However, the models were developed and evaluated within a single cohort, and the limited sample size and absence of external validation restrict the generalizability of these findings. Although the best-performing models explained approximately half of the observed variance in IGF-1 SDS, a substantial proportion remained unexplained, reflecting the complexity of IGF-1 dynamics during the maintenance phase and puberty. In current clinical practice, GH dose adjustments are not based solely on IGF-1 levels but are interpreted together with growth response, pubertal development, treatment adherence, and other clinical factors. A prediction error of approximately 0.6 to 0.7 SDS would therefore currently limit the use of these models as stand-alone tools for dose adjustment. The primary aim of the study was not to develop a dosing algorithm for clinical use but to evaluate whether IGF-1 levels during the maintenance phase and puberty can be predicted and to identify predictors of IGF-1 levels over time. The present findings demonstrate that interpretable modeling approaches can explain a substantial proportion of the observed variation in IGF-1 levels during a treatment phase where regulation is influenced by multiple interacting factors. Further validation in larger cohorts will be required before clinical implementation can be considered, but these results provide new insight into the prediction of IGF-1 levels during later phases of GH treatment and may support the future development of more individualized treatment strategies.

Subject of Research: Prediction of IGF-1 levels during growth hormone therapy in boys using interpretable machine learning

Article Title: Interpretable machine learning identifies predictors of IGF-1 during growth hormone therapy in boys

Article References: Ly, H.-J., Suvilehto, J. T., Skyman, B., Ankarberg-Lindgren, C., Fors, H., Havsol, J., & Dahlgren, J. (2026). Interpretable machine learning identifies predictors of IGF-1 during growth hormone therapy in boys. Frontiers in Endocrinology, 17, Article 1873245. https://doi.org/10.3389/fendo.2026.1873245

Image Credits: AI Generated

DOI: 10.3389/fendo.2026.1873245

Keywords: growth hormone therapy, IGF-1, machine learning, pediatric endocrinology, prediction model, personalized medicine, Elastic Net, explainable boosting machine, puberty, maintenance phase, cross-validation, boys

The core of the argument is that metabolic dysregulation acts as a selective pressure on premalignant tissue, not merely as a passive risk factor in the conventional epidemiologic sense. Chronic hyperinsulinemia increases bioavailable insulin-like growth factor 1 (IGF-1) and sustains activation of the PI3K–AKT–mTOR and RAS–MAPK signaling cascades, the two master growth pathways that drive proliferation and survival. Paradoxically, in tissues where insulin resistance has developed, mitogenic sensitivity is preserved even as glucose disposal falters, creating an environment highly permissive to clonal selection. Elevated inflammatory mediators, including interleukin-6, leptin, and other adipokines, further amplify proliferative signaling while dampening apoptotic responses. A systematic review using the hyperinsulinemic–euglycemic clamp confirmed that severe insulin resistance is present in patients with cancer relative to matched controls, with a mean glucose disposal rate of 4.7 versus 7.5 mg/kg/min, and limited evidence suggests this metabolic adaptation may precede clinical diagnosis rather than follow it.

The mechanism by which metabolic state becomes inscribed into cellular behavior runs through the epigenome. Metabolic intermediates—S-adenosylmethionine (SAM), acetyl-CoA, α-ketoglutarate, and NAD+—serve as obligate substrates for chromatin-modifying enzymes, continuously coupling a cell’s metabolic condition to its epigenetic landscape. Shifts in one-carbon metabolism can directly alter histone methylation and downstream transcription across every cell division that occurs during the years of subclinical dysregulation preceding diagnosis. Among the relevant modifications, the authors focus on histone H3 lysine 9 (H3K9) methylation, catalyzed by the methyltransferases EHMT1 and EHMT2—known as GLP and G9a—which deposit mono- and dimethyl marks using SAM as the methyl donor. H3K9me2 at apoptotic and differentiation loci has been linked to drug resistance in prior studies, making this mark a candidate bridge between metabolism and treatment failure.

Two distinct inputs shape this chromatin landscape, and the authors are careful to separate them. Hypoxia is the driver of H3K9me2 gain: low oxygen stabilizes the G9a protein and increases H3K9me2 at tumor-suppressor and apoptotic loci, effectively silencing the genes that would otherwise command damaged or abnormal cells to die. SAM availability works separately. When SAM is limiting, EHMT1/2 preferentially preserve H3K9me1 while higher-order di- and trimethylation decline, so SAM depletion does not itself add to H3K9me2. One-carbon and SAM status is therefore best understood as setting the available H3K9me1 substrate pool, whereas hypoxia-stabilized G9a generates the resistance-associated H3K9me2. The consequence of both processes is an elevated apoptotic threshold and an enrichment of epigenetically primed, apoptosis-resistant cells before a tumor is histologically apparent or clinically detected. The authors note an unresolved gap: whether G9a regulation in premalignant epithelial compartments mirrors the dynamics seen in metabolic tissues such as liver and adipose, where G9a expression drops under high-fat conditions, has not been systematically characterized.

A compelling precedent for the idea that metabolic intervention can undo epigenetic hardening comes from pancreatic cancer, where pharmacologic inhibition of the metabolic pathway driving epigenomic reprogramming reversed both the chromatin state and the malignant phenotype. Against this mechanistic backdrop, the clinical prediction converges: tumors arising in metabolically dysregulated tissue should harbor larger fractions of pre-existing resistant subclones. Parallel mechanisms, not competing ones, produce a cell population more likely to progress, survive dormancy, and resist treatment. In this framing, resistance is less a response to therapy than the clinical unveiling of a cellular architecture established years earlier.

The population-scale data that speak to this hypothesis have arrived, perhaps unexpectedly, through the GLP-1 receptor agonists, the drug class behind the current obesity-treatment revolution. These agents reduce hyperinsulinemia, attenuate IGF-1 bioavailability, and suppress systemic inflammatory markers, making them the most informative pharmacologic probe of the metabolic hypothesis—though the authors stress they are not its therapeutic endpoint. The emerging observational signal is provocative. A 2026 meta-analysis of 24 observational studies enrolling nearly 4 million patients found a 30 percent reduction in obesity-related cancer risk, and a large retrospective cohort confirmed reduced overall cancer incidence in adults with obesity, with a hazard ratio of 0.83. Body mass index–independent reductions in acute myeloid leukemia and breast cancer incidence, persisting after adjustment for metabolic covariates, hint at a mechanism operating through metabolic signaling rather than adiposity reduction alone, though these data remain preliminary conference abstracts. In a preclinical colitis-associated carcinogenesis model, the dual agonist tirzepatide reduced tumor burden by suppressing metabolic pathways without inducing weight loss.

The most striking clinical evidence comes from a retrospective cohort of 841,831 patients with breast cancer drawn from the TriNetX network, in which propensity-matched GLP-1RA users demonstrated approximately 60 percent lower all-cause mortality at both 5 and 10 years compared with non-users, alongside a large relative improvement in recurrence-free survival. A finding of this magnitude in a dataset of this size commands attention and scrutiny, all the more so given its retrospective design. Intriguingly, when GLP-1RA users were compared not with untreated controls but with users of sodium-glucose cotransporter 2 inhibitors—another drug class that corrects insulin resistance through a distinct mechanism—the survival difference was attenuated, leaving only modest residual benefit after covariate adjustment. The implication is subtle but potentially transformative: if two mechanistically distinct agents that share the common property of metabolic normalization produce convergent oncologic signals, then the operative variable may not be either drug, but the metabolic environment that both drugs correct.

The counterweight is substantial, and the authors confront it directly. A meta-analysis of 48 randomized controlled trials enrolling 94,245 participants found no effect of GLP-1RAs on obesity-related cancer incidence, and a separate RCT-based meta-analysis reported increased thyroid and colorectal cancer risk, with Mantel–Haenszel odds ratios of 1.55 and 1.27 respectively. The authors attribute these discrepancies to trial design rather than failure of the mechanism: the trials were not designed with cancer endpoints, had inadequate follow-up durations for solid tumor latency, and lacked metabolically enriched patient selection. But they are careful not to treat these as exculpations of the null result. The metformin precedent is instructive: the MA.32 trial and a subsequent meta-analysis of 22 randomized trials confirmed no benefit on disease-free or overall survival, despite a compelling mechanistic rationale. The intervention was simply not potent enough. By that logic, meaningfully reversing the metabolic selective pressure may require a more potent, broader-acting intervention deployed in a metabolically high-risk population.

What elevates the hypothesis above speculation is its alignment with the somatic evolution literature, which indicates that resistance predominantly pre-exists. Multiple orthogonal approaches—cell-free DNA analysis, high-complexity barcode tracing, and single-cell sequencing—have collectively demonstrated that acquired resistance frequently arises from pre-existing subclones selected by therapeutic pressure. The same single-cell analyses that identify pre-existing resistant genotypes also document treatment-associated transcriptional reprogramming, indicating that selection and adaptation operate together. What has been missing is a specific account of how the resistant architecture becomes established in the first place, and the metabolic framework supplies one: chronic metabolic stress creates conditions in which EHMT1/2 gain the upper hand in premalignant tissue, concentrating repressive marks at genes governing cell death and differentiation, yielding a subpopulation already primed to resist apoptosis before any treatment is given. These clones, the authors argue, might not be generated by treatment but revealed by it. The framework explicitly does not claim to account for reversible drug-tolerant persister states or to exclude resistance genuinely acquired during treatment.

The authors specify the experiment that would directly test the hypothesis, and it has not been performed: correlating pretreatment fasting insulin, HOMA-IR, and IGF-1/IGF-binding protein 3 ratio with baseline subclonal architecture, H3K9me2 state, circulating tumor DNA heterogeneity, and treatment outcome in metabolically unselected patients initiating systemic therapy. Reverse causation predicts metabolic abnormality follows neoplastic change; this model requires the opposite ordering. Treatment-induced plasticity predicts resistant chromatin states emerge only after exposure; this model predicts they are demonstrable in treatment-naive tissue. Each prediction is testable, and none has yet been tested directly. The urgency is sharpened by young adults with early-onset colorectal cancer who are neither obese nor diabetic, a cohort for whom conventional risk factors do not suffice as explanation, and by the CHALLENGE trial, which provided the first level I evidence in stage III and high-risk stage II colon cancer that structured post-chemotherapy exercise—an intervention known to reduce fasting insulin, IGF-1 bioavailability, and inflammatory markers—improves disease-free survival. A cautionary note comes from the neoadjuvant setting, where concurrent GLP-1RA use during chemoimmunotherapy for early-stage triple-negative breast cancer was associated with reduced pathologic complete response in one retrospective cohort, though a subsequent multi-institution study found diabetes mellitus, not GLP-1RA use, independently associated with reduced response. The authors are explicit that the evidence does not yet establish that GLP-1 receptor agonists prevent recurrence or resistance, and that patients with established metabolic indications should be treated for those indications on their own merits. But the central untested prediction—that pretreatment metabolic state correlates with baseline subclonal architecture, chromatin state, and treatment outcome—is tractable, fundable, and immediately actionable, and the answers will matter whatever they turn out to be.

Subject of Research: How chronic metabolic dysregulation epigenetically primes pre-existing cancer treatment resistance before therapy

Article Title: Metabolic oncology: clonal selection and the pre-existing origins of cancer resistance

Article References: Perez, C. A., & Khaled, A. R. (2026). Metabolic oncology: clonal selection and the pre-existing origins of cancer resistance. Frontiers in Oncology, 16, Article 1951576. https://doi.org/10.3389/fonc.2026.1951576

Image Credits: AI Generated

DOI: 10.3389/fonc.2026.1951576

Keywords: cancer metabolism, treatment resistance, clonal selection, epigenetics, H3K9 methylation, EHMT1/EHMT2, GLP-1 receptor agonists, hyperinsulinemia, IGF-1, tumor evolution, metformin, early-onset colorectal cancer

The distinction matters because the traditional approach to molting—simply removing all feed for a period of days—has come under sustained scrutiny from welfare scientists and regulators alike. Complete feed withdrawal triggers a cascade of stress responses that go well beyond hunger: birds deplete hepatic glycogen within hours, begin mobilizing lipid stores at an accelerated rate, and experience activation of the hypothalamic–pituitary–adrenal axis, the body’s central stress machinery. Corticosterone, the primary glucocorticoid in birds, rises sharply under these conditions, and chronically elevated corticosterone is associated with immunosuppression, increased susceptibility to Salmonella and other bacterial pathogens, and behavioral signs of distress. These concerns have driven decades of research into alternative molting protocols that achieve reproductive regression without the full metabolic shock of fasting.

The two main alternatives fall into distinct categories. Quantitative restriction, exemplified in this study by a reduced allocation of the regular commercial diet, limits the total amount of nutrients a bird consumes while maintaining normal diet composition. Dietary dilution, by contrast, uses ingredients such as alfalfa or wheat bran that are high in fiber and low in metabolizable energy, allowing birds to eat ad libitum while still receiving far fewer usable calories and nutrients per gram of feed. Sorghum, a grain with lower energy density than typical corn-soy layer diets, occupies an intermediate position. The Mexican research team grouped these five programs into three physiological categories—absolute restriction, moderate restriction, and nutrient dilution—and the grouping proved analytically powerful, revealing that programs within the same category produced more similar endocrine and metabolic signatures than programs sharing similar feeding mechanics but different restriction severity.

The speed at which birds reached the target body weight loss is itself informative. Feed withdrawal achieved the target in roughly seventeen days, and alfalfa nearly matched that pace at just under nineteen days, while restricted commercial feed took almost twenty-nine days. This pattern suggests that the effective energy deficit, not the mere presence or absence of feed in the trough, governs the pace of reproductive involution. Alfalfa’s rapid effect despite continuous feed availability likely reflects its very low energy density and high fiber content, which together impose a substantial nutrient dilution even when birds consume large volumes of the diet. For producers weighing welfare considerations against operational timelines, this finding carries practical weight: dilution-based programs need not be synonymous with slow or ineffective molting.

The endocrine measurements reveal the depth of coordination underlying these changes. Under absolute restriction, estradiol fell to 76.96 picograms per milliliter and progesterone to 0.34 nanograms per milliliter, concentrations consistent with near-complete suppression of ovarian steroidogenesis. These sex steroids are produced by the hierarchical follicles of the ovary, and their collapse signals follicular atresia—the regression and resorption of the yolk-filled follicles that would otherwise mature into eggs. Progesterone, in particular, is essential for ovulation, and its near-disappearance marks the functional end of the laying cycle. Meanwhile, the anabolic hormones that normally support egg production also declined: insulin dropped to 6.58 micro-international units per milliliter, insulin-like growth factor-1 to 33.82 nanograms per milliliter, and triiodothyronine to 1.84 nanograms per milliliter. Each of these hormones acts as a nutritional signal to the reproductive axis; insulin and IGF-1 promote follicular growth and steroidogenic capacity, while T3 reflects metabolic rate and thyroid status. Their simultaneous decline represents the body withdrawing the endocrine permission required for reproduction to continue.

On the catabolic side of the ledger, corticosterone rose to 12.21 nanograms per milliliter, non-esterified fatty acids climbed to 1.24 milliequivalents per liter, and urea reached 8.45 milligrams per deciliter. Elevated NEFA indicates active lipolysis—the breakdown of adipose tissue to supply energy substrates—while elevated urea points to protein catabolism, the mobilization of muscle and other protein reserves. Together with the suppressed anabolic hormones, these metabolites sketch a systemic shift from an anabolic, reproduction-oriented state to a catabolic state in which nutrients are reallocated toward maintenance and survival. This is the metabolic logic of molting: the bird cannot sustain the enormous energetic cost of egg production, which in a high-producing layer can exceed the energy content of the entire diet, so the reproductive apparatus is dismantled and resources are redirected.

The correlation analyses add a layer of insight that single-hormone measurements cannot provide. Positive associations between reproductive and metabolic biomarkers, with coefficients ranging from 0.35 to 0.79, indicate that reproductive hormones and metabolic hormones rise and fall together across the molting timeline—when insulin and IGF-1 are high, estradiol and progesterone tend to be high as well. The negative associations involving corticosterone and NEFA, with coefficients between −0.44 and −0.71, are equally telling: as the stress hormone and the lipid mobilization marker climb, reproductive hormones fall. These relationships held across the different restriction categories, but regression analyses showed that the precise coupling patterns differed by program, suggesting that the endocrine–metabolic axis is not a single fixed circuit but a flexible network whose behavior depends on the nature of the nutritional challenge.

Triiodothyronine deserves particular attention in this context. As the active thyroid hormone governing metabolic rate, T3 typically falls during energy restriction as part of a conserved adaptive response to reduce energy expenditure. Its decline during molt induction in this study, most pronounced under absolute restriction, aligns with this classical response and reinforces the interpretation that the birds were experiencing genuine energetic stress rather than merely a change in diet composition. The fact that moderate restriction produced the mildest alterations across the endocrine panel suggests that quantitative restriction of the regular diet, while slower to achieve the target weight loss, imposes a gentler physiological burden than either complete fasting or aggressive nutrient dilution.

Prolactin, the remaining hormone in the panel, adds nuance to the picture. In birds, prolactin is associated with incubation behavior and the suppression of ovarian function, and its dynamics during molting can vary depending on the stimulus. The inclusion of prolactin in the measurement battery reflects an awareness that reproductive regression is not simply the absence of stimulatory hormones but may also involve the presence of inhibitory ones. How prolactin responds to different restriction severities may help explain why some programs produce more complete or more durable reproductive regression than others.

The post-molt recovery phase, though less emphasized in the reported results, is arguably where the practical value of these findings ultimately resides. A molting program that induces regression but impairs subsequent ovarian recovery would be counterproductive regardless of its welfare profile. The finding that different programs produce distinct patterns of endocrine–metabolic coupling raises the possibility that the trajectory of recovery—how quickly insulin, IGF-1, T3, estradiol, and progesterone rebound, and how the metabolic profile normalizes—may also differ by program. If the depth of endocrine suppression during molt induction predicts the speed or quality of post-molt laying performance, then the restriction category could serve as a practical guide for selecting molting protocols that balance welfare concerns, metabolic stress, and productive outcomes.

More broadly, the study contributes to a growing recognition that induced molting should be understood as a coordinated process of endocrine–metabolic reorganization rather than a simple consequence of body weight loss. The body weight target, long used as the operational endpoint of molting programs, is in this view merely a visible proxy for a deeper physiological transition. Two programs can produce identical weight loss while imposing very different endocrine burdens, and the metabolic and stress signatures captured in this study provide a more informative basis for comparing them. As welfare regulations increasingly restrict feed withdrawal in major egg-producing regions, and as producers seek alternatives that preserve both flock health and post-molt productivity, studies that map the full endocrine–metabolic response to different restriction strategies offer a foundation for evidence-based protocol selection.

The work also illustrates the value of studying multiple axes simultaneously. Reproductive hormones, metabolic hormones, stress mediators, and circulating metabolites are typically measured in separate investigations, each with its own literature and its own specialist audience. By measuring all of these variables in the same birds across the same timeline, and by analyzing their correlations and coupling patterns, the researchers captured the integrative physiology that individual-axis studies necessarily miss. The result is a more complete account of what induced molting actually does to a hen—not just that she stops laying, but how the entire hormonal and metabolic apparatus of the body is reorganized to make that stoppage possible, and how the nature of the nutritional restriction shapes the character of that reorganization.

For the poultry industry, the practical implications extend to program design. If moderate restriction produces the mildest physiological alterations while still achieving reproductive regression, albeit more slowly, then programs based on restricted commercial feed may offer a favorable welfare-to-efficacy ratio for operations where timeline flexibility exists. Conversely, where rapid molting is operationally necessary, nutrient dilution with alfalfa offers a non-fasting alternative that approaches the speed of feed withdrawal while presumably avoiding its most severe endocrine and metabolic extremes. The intermediate responses observed under nutrient dilution suggest that this category occupies a genuine middle ground, and the differences between alfalfa and wheat bran within that category hint that fiber source and composition may further modulate the response in ways that merit continued investigation.

Subject of Research: Endocrine and metabolic responses of laying hens to different induced molting programs

Article Title: Endocrine–metabolic integration and reproductive regression in laying hens subjected to different molt induction programs

Article References: Hernández, A., Ordaz, G., Villalba, C. A., Padilla, S., Gutiérrez, E., Val, D., & Juárez, A. (2026). Endocrine–metabolic integration and reproductive regression in laying hens subjected to different molt induction programs. Frontiers in Animal Science, 7, Article 1963978. https://doi.org/10.3389/fanim.2026.1963978

Image Credits: AI Generated

DOI: 10.3389/fanim.2026.1963978

Keywords: laying hens, induced molting, endocrinology, metabolism, animal welfare, poultry science, reproductive regression, corticosterone, IGF-1, insulin, NEFA, alfalfa

The hormone in question is insulin-like growth factor-1, or IGF-1, a small protein secreted largely by the liver that circulates in the blood and acts as a master anabolic signal for skeletal muscle. When IGF-1 binds to receptors on muscle fibers, it activates the AKT/mTOR pathway, an intracellular circuit that drives protein synthesis, cell growth, and repair. When that signal weakens, muscles tip toward atrophy, ramping up destruction machinery such as the E3 ubiquitin ligases Atrogin-1 and MuRF1, which tag contractile proteins for degradation. The Korean team’s central finding is that two commonly prescribed statins, lovastatin and atorvastatin, appear to disrupt this liver-to-muscle endocrine axis by first aging the liver.

Cellular senescence is a state in which a cell stops dividing but does not die, instead accumulating damage markers and secreting a cocktail of inflammatory and regulatory molecules known as the senescence-associated secretory phenotype, or SASP. In the new work, the researchers treated hepatocytes with lovastatin and atorvastatin and observed the classic fingerprints of senescence: increased activity of senescence-associated beta-galactosidase, an enzyme used as a standard histochemical marker of aged cells, and elevated expression of p21 and p16, two tumor-suppressor proteins that enforce the senescence program by halting the cell cycle. These changes were seen both in cultured liver cells and in liver tissue from animals exposed to the drugs, indicating that the phenomenon is not merely an artifact of the culture dish.

The most striking result came when the team catalogued what the senescent hepatocytes were secreting. Among the many components of the SASP, one factor stood out for moving in the wrong direction: IGF-1 was selectively and significantly reduced. In other words, rather than gaining inflammatory secretions, the statin-aged liver cells lost a key growth factor output. Because circulating IGF-1 is produced predominantly by the liver, a drop in hepatic IGF-1 expression translates directly into lower levels of the hormone in the bloodstream, potentially affecting tissues throughout the body that rely on it for maintenance and repair.

To test whether this hormonal shortfall actually harms muscle, the researchers set up a transwell coculture system, an experimental arrangement in which two cell types share a medium but are separated by a porous membrane, allowing soluble factors to pass while keeping the cells physically apart. When senescent AML12 mouse hepatocytes were cocultured with C2C12 myoblasts, the muscle cells’ ability to differentiate into myotubes was impaired, the resulting myotubes were thinner, and the muscle atrophy markers Atrogin-1 and MuRF1 were upregulated. Because the cells never touched, the effect must have been mediated by secreted factors — consistent with the idea that the senescent liver cells’ diminished IGF-1 output starves muscle of an essential growth signal.

The in vivo experiments reinforced the picture. The team exposed animals to a combination of lovastatin and ezetimibe, a cholesterol-absorption inhibitor that is often co-prescribed with statins to achieve greater low-density lipoprotein reduction. In the livers of these animals, the area staining positive for senescence-associated beta-galactosidase expanded, p21 and p16 expression rose, and circulating IGF-1 fell. Downstream, in the tibialis anterior muscle — a standard lower-leg muscle used in rodent studies of skeletal muscle physiology — the researchers measured a reduced average fiber cross-sectional area and a size distribution shifted toward smaller fibers, exactly what one expects when atrophy outpaces growth.

The molecular readout in the muscle told a coherent mechanistic story. AKT/mTOR pathway activation was diminished, meaning the anabolic circuit that IGF-1 normally engages had gone quiet, and the atrophy-associated proteins Atrogin-1 and MuRF1 were elevated, indicating that the ubiquitin-proteasome degradation machinery had been switched on. Together, these changes describe a muscle caught between reduced protein synthesis and increased protein breakdown — the biochemical definition of atrophy. The authors propose that this cascade constitutes a liver-to-muscle endocrine axis: statin-induced hepatic senescence suppresses IGF-1, and the resulting attenuation of IGF-1 signaling in muscle secondarily impairs myogenesis and promotes wasting.

The findings carry several important caveats and implications. First, the study was conducted in cell culture and in animal models, so the results will need to be confirmed in human studies before they can reshape clinical practice; the authors themselves frame the work as supporting a potential axis rather than proving it in patients. Second, the observation that ezetimibe was part of the in vivo regimen raises questions about how much of the hepatic effect is attributable to statin-specific inhibition of HMGCR, the enzyme that both statins target and that sits at the head of the mevalonate pathway, versus broader metabolic stress. HMGCR catalyzes a rate-limiting step in the production of mevalonate, from which cells synthesize not only cholesterol but also isoprenoid intermediates needed for protein prenylation — processes implicated in cell survival and stress responses. Blocking this pathway in hepatocytes may therefore trigger senescence through mechanisms that go well beyond cholesterol lowering itself.

For the millions of people who take statins, the study should not prompt anyone to stop their medication; the cardiovascular benefits of statins are firmly established, and statin-associated muscle symptoms, while real, affect a minority of users and are often manageable by adjusting dose or switching agents. But the research does suggest a new therapeutic frontier. If hepatic senescence is a driver of muscle complications, then drugs that clear senescent cells — so-called senolytics — or agents that dampen the senescence program might one day protect muscle in susceptible patients. Alternatively, restoring IGF-1 signaling, whether by supplementing the hormone, boosting its hepatic production, or activating AKT/mTOR downstream, could counteract the atrophy signal at its source. The authors explicitly propose targeting hepatic senescence or restoring IGF-1/AKT/mTOR activity as candidate strategies to mitigate statin-associated myopathy.

More broadly, the work adds to a growing appreciation that aging-like states induced in one organ can propagate systemically through endocrine signals. The liver, as the body’s metabolic factory and a major source of circulating growth factors, is uniquely positioned to broadcast its internal state to muscle, bone, and brain. A drug that quietly ages hepatocytes may therefore have consequences far beyond lipid numbers on a lab report. As the population on long-term statin therapy continues to grow — and as those patients themselves age — understanding how hepatic senescence reshapes the hormonal environment of muscle could prove essential not only for making statins safer but for preserving strength and independence in later life. The Korean team’s liver-muscle axis offers a testable framework for that effort, and it transforms a side effect long dismissed as a pharmacological mystery into a biological pathway that can, in principle, be measured, modeled, and targeted.

Subject of Research: Statin-induced hepatic senescence and reduced IGF-1 signaling driving skeletal muscle atrophy

Article Title: Hepatic senescence triggered by statins decreases systemic IGF-1 signaling to drive skeletal muscle atrophy

Article References: Kim, W.-K., Yeon, M., Yoo, Y., Shin, H.-B., Yang, Y. R., & Seo, Y.-K. (2026). Hepatic senescence triggered by statins decreases systemic IGF-1 signaling to drive skeletal muscle atrophy. Cell Death Discovery. https://doi.org/10.1038/s41420-026-03399-y

Image Credits: AI Generated

DOI: 10.1038/s41420-026-03399-y

Keywords: statins, hepatic senescence, IGF-1, skeletal muscle atrophy, AKT/mTOR signaling, SASP, Atrogin-1, MuRF1, HMGCR, liver-muscle axis, myopathy, cell senescence

The review, led by Barbara Kamińska together with Aleksandra Białczyk and Rafał Czajkowski, systematically searched PubMed and Web of Science from database inception through April 16, 2025, without language or date restrictions. After screening 1,264 initially identified records, the team retained 33 original observational studies, 12 cross-sectional and 21 case-control investigations, published between 2011 and 2024. Sample sizes ranged from 30 to 896 participants. Geographically, the evidence base was heavily skewed: 26 studies came from Asia, five from Europe, and only two from the Americas, a concentration the authors flag as a potential limitation for generalizability.

The headline numbers are striking. Among the 17 studies that reported the prevalence of metabolic syndrome, a cluster of risk factors including central obesity, elevated blood pressure, impaired glucose metabolism, and dyslipidemia, 505 of 1,473 patients with vitiligo, or 34.3 percent, met diagnostic criteria, most commonly those set by the NCEP ATP III guidelines. In control groups, by contrast, only 240 of 1,289 participants, or 18.6 percent, qualified. Thirteen of the 15 studies providing comparative data found higher rates of metabolic syndrome in the vitiligo groups. Individual study estimates varied widely, from 6.7 percent to 50.7 percent, a spread the authors attribute to differing diagnostic thresholds, patient selection, and regional metabolic backgrounds.

Insulin resistance, the reduced ability of cells to respond to normal circulating levels of insulin, told a similar story. The most widely used proxy, the Homeostasis Model Assessment of Insulin Resistance, or HOMA-IR, is calculated as fasting plasma insulin multiplied by fasting plasma glucose and divided by 22.5. Across seven studies that applied HOMA-IR cut-off values, insulin resistance was identified in 279 of 494 patients with vitiligo, or 56.5 percent, versus 125 of 380 controls, or 32.9 percent. In every one of the six comparative studies, the prevalence was higher in the vitiligo group. Reported rates among patients ranged from 26.7 percent to 88.7 percent, and one study that excluded people with diabetes still found insulin resistance in 63 percent of its vitiligo cohort.

Supporting biochemical data reinforced the pattern. Across ten studies, mean fasting glucose in vitiligo patients averaged 95.66 mg/dL compared with 78.5 mg/dL in controls, while mean fasting insulin averaged 12.96 µIU/mL against 9.01 µIU/mL in control participants. Lipid abnormalities also appeared repeatedly: decreased HDL cholesterol, elevated LDL-to-HDL ratios, and increased triglycerides were frequently documented. Some studies reported higher insulin and C-peptide levels even in non-diabetic patients, hinting at early metabolic dysregulation, although at least one investigation observed a more favorable lipid profile in vitiligo patients, underscoring the inconsistency across the literature.

Whether these metabolic changes track with the severity or duration of vitiligo remains contested. Several studies found that active disease, greater body surface area involvement, and higher scores on the Vitiligo Area Scoring Index or the Vitiligo Disease Activity score predicted metabolic syndrome, insulin resistance, or elevated levels of inflammatory and metabolic biomarkers such as FABP4, VAP-1, and YKL-40. Disease severity has also been identified as an independent predictor of metabolic syndrome and subclinical atherosclerosis, and one study reported a strong correlation between serum homocysteine and VASI scores. Yet other investigations found no relationship between severity measures and metabolic indicators, and the evidence on disease duration is similarly divided, with some studies linking longer duration to metabolic risk and one even finding metabolic syndrome more common in patients with shorter disease duration, possibly reflecting higher disease activity early in its course.

The biological plausibility of a skin-metabolism connection rests on shared mechanisms of oxidative stress, chronic inflammation, and mitochondrial dysfunction. Reactive oxygen species are believed to sensitize melanocytes to immune-mediated destruction in vitiligo, and the same redox imbalance promotes serine phosphorylation of insulin receptors, disrupting insulin signaling and impairing glucose metabolism. Proinflammatory cytokines, including interleukin-1, interleukin-6, and tumor necrosis factor-alpha, are elevated in both conditions and further amplify the pro-oxidative state. Melanocytes resident in adipose tissue normally exert anti-inflammatory effects and reduce reactive oxygen species; their loss may contribute to increased oxidative stress and lipid peroxidation throughout the body.

Recent work has pushed this mechanistic story to the cellular level. Keratinocytes, melanocytes, and fibroblasts all express functional insulin and insulin-like growth factor 1 receptors, implicating insulin-dependent signaling in skin homeostasis. Experimental data show that IGF-1 can reduce oxidative damage and inflammatory cytokine production in skin models, while clinical studies report decreased serum IGF-1 levels in patients with vitiligo. Most provocatively, a 2025 study by Caputo and colleagues provided the first direct evidence of insulin resistance in keratinocytes and melanocytes derived from vitiligo patients, demonstrating impaired mitochondrial ATP production and altered cellular energy sensing despite normal extracellular glucose levels. This suggests that intrinsic mitochondrial dysfunction may underlie both the cutaneous and systemic metabolic features of the disease, opening potential avenues for therapies aimed at metabolic reprogramming.

The authors are careful about what the evidence can and cannot show. Because of considerable heterogeneity in study designs, diagnostic criteria for metabolic syndrome, and HOMA-IR thresholds, which ranged from greater than 1.93 to greater than 2.9 across studies, a quantitative meta-analysis was not feasible, and the findings were synthesized narratively. Most included studies were cross-sectional and focused on disease presence rather than progression, so causal relationships remain uncertain. Methodological quality was assessed with the Newcastle-Ottawa Scale by two independent reviewers, with a third resolving disagreements. The reviewers also note that most studies did not specify whether individuals with diabetes were excluded or analyzed separately, complicating interpretation of some glucose data, and that the geographic concentration of studies in Asia and the Middle East may limit how broadly the conclusions apply.

Even with those caveats, the practical message for clinicians is clear. The review argues that metabolic screening deserves consideration in patients with vitiligo, particularly those with active, extensive, or long-standing disease, much as it is now routine for patients with severe psoriasis. If future prospective, multicenter studies with standardized definitions confirm the association, and clarify whether metabolic disturbances play a causal role in vitiligo pathogenesis or progression, targeted metabolic interventions might one day improve outcomes for a disease currently treated almost exclusively as a disorder of pigmentation. For the millions of people living with vitiligo worldwide, the skin may finally be recognized as a window into the body’s deeper metabolic health.

Subject of Research: Association between vitiligo and cardiometabolic risk, specifically insulin resistance and metabolic syndrome

Article Title: Insulin resistance and metabolic syndrome in patients with vitiligo: a systematic review and narrative synthesis

Article References: Kamińska, B., Białczyk, A., & Czajkowski, R. (2026). Insulin resistance and metabolic syndrome in patients with vitiligo: a systematic review and narrative synthesis. Archives of Dermatological Research, 318(1), Article 455. https://doi.org/10.1007/s00403-026-04909-9

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04909-9

Keywords: vitiligo, metabolic syndrome, insulin resistance, HOMA-IR, melanocytes, oxidative stress, autoimmune disease, cardiometabolic risk, systematic review, inflammation, IGF-1, dermatology

The review, led by Seung-Jae Lee of the Korea Research Institute of Bioscience and Biotechnology, synthesizes decades of research into the biochemical composition of deer antler velvet, commonly abbreviated DAV. The tissue is a biochemical treasure chest: it contains abundant type I and type II collagen, a broad spectrum of bioactive peptides, and an impressive array of growth factors including insulin-like growth factor-1 (IGF-1), epidermal growth factor (EGF), transforming growth factor-beta (TGF-β), and several fibroblast growth factors. Alongside these sit glycosaminoglycans such as chondroitin sulfate and hyaluronic acid, essential and non-essential amino acids, minerals including calcium, phosphorus, magnesium, zinc, and iron, phospholipids, gangliosides, polysaccharides, nucleotides, and sialic acid. Each of these compound classes has documented biological activity in laboratory settings, which explains why DAV has attracted attention for applications ranging from joint health to neuroprotection.

The mechanistic story emerging from preclinical research is coherent, at least on paper. Growth factors found in DAV are known to engage canonical signaling cascades such as PI3K/Akt, MAPK/ERK, and JAK/STAT, pathways that govern cell proliferation, extracellular matrix synthesis, and tissue remodeling. In cell culture and animal models, DAV-derived fractions have been shown to stimulate osteoblast proliferation, promote chondrogenesis, accelerate wound closure, and support angiogenesis. Meanwhile, DAV peptides and polysaccharides appear to modulate redox balance by upregulating antioxidant enzymes like superoxide dismutase, catalase, and glutathione peroxidase, and to suppress inflammation through inhibition of the NF-κB pathway and modulation of MAPK signaling, reducing pro-inflammatory cytokines such as TNF-α, IL-6, and IL-1β while boosting the anti-inflammatory mediator IL-10. Gangliosides and phospholipids in the tissue have been linked to neuronal survival and synaptic plasticity, and rodent studies report improvements in learning and memory as well as protection against chemically induced neuronal damage.

But here is where the review delivers its most sobering message: biological plausibility is not clinical proof. The overwhelming majority of the evidence for DAV’s celebrated effects comes from in vitro experiments and animal models, with comparatively few well-controlled human trials. One of the few clinical studies examining physical performance, conducted with just 38 participants, produced outcomes that were not entirely consistent, and its small sample size limits statistical power and generalizability. Systematic reviews of randomized controlled studies of deer and elk velvet antler supplements have similarly found the human evidence base thin and heterogeneous. For conditions such as osteoporosis, cartilage degeneration, neurodegenerative disease, or chronic inflammation, no large-scale randomized controlled trials with clinically meaningful endpoints currently exist.

A deeper problem lurks beneath the evidence gap: the question of bioavailability. The star molecules of DAV, particularly IGF-1 and other peptide growth factors, are proteins, and proteins face a hostile journey through the human gastrointestinal tract, where digestive enzymes typically cleave them into fragments long before they could reach systemic circulation intact. The review emphasizes that the extent to which intact growth factors survive digestion and achieve physiologically relevant concentrations in the bloodstream remains fundamentally uncertain. This means that some observed biological effects may actually reflect smaller peptide fragments or indirect signaling modulation rather than direct systemic growth factor activity. Encapsulation, protective co-formulation, and controlled-release delivery systems are being explored to improve stability and absorption, but comprehensive pharmacokinetic data on DAV-derived growth factors in humans remain scarce.

Compounding the bioavailability problem is the issue of standardization. Deer antler velvet is not a single, uniform substance. Its composition varies with species, the age of the animal, the stage of antler growth at harvest, diet, seasonal factors, and processing methods. Hot water extraction, the most common traditional approach, effectively solubilizes proteins, peptides, and polysaccharides but can partially denature heat-sensitive growth factors. Ethanol extraction enriches lipid-soluble compounds but may reduce overall protein content. Modern techniques such as enzymatic hydrolysis, ultrasonic-assisted extraction, and supercritical CO₂ extraction offer improved yields and selectivity, with enzymatically hydrolyzed preparations showing higher immunomodulatory and osteogenic activity in some studies. Yet even with these advances, batch-to-batch reproducibility remains elusive, and internationally harmonized quality standards for DAV do not yet exist. Analytical tools including high-performance liquid chromatography, ELISA, and mass spectrometry are available for compositional profiling, but no universally accepted marker compounds have been established.

Safety data, while generally reassuring, carry their own caveats. Toxicological assessments in rodents report low acute and subchronic toxicity, with minimal adverse effects on liver and kidney function, hematological parameters, and behavior even at relatively high doses. However, long-term studies covering reproductive toxicity, carcinogenicity, and large-scale human safety are limited. The presence of growth-promoting molecules raises theoretical endocrine and oncogenic concerns, even though conventional DAV supplementation has not been conclusively associated with such adverse outcomes in humans. Allergenicity is biologically plausible given the tissue’s protein content, though documented severe allergic responses appear uncommon. The review also notes that growth-associated factors have attracted attention in athletic contexts regarding anti-doping compliance, although current evidence does not clearly demonstrate supraphysiological systemic effects from oral consumption.

The regulatory landscape is equally fragmented. In China and Korea, DAV is embedded within traditional medicinal systems and functional product frameworks, while in the United States and the European Union it is typically classified as a dietary supplement or natural health product subject to good manufacturing practices and restricted health claims. This patchwork of classifications, combined with compositional variability, creates a regulatory bottleneck: without quantified, reproducible marker compounds such as defined peptide fractions or measured IGF-1 levels, dose standardization and cross-border market integration remain difficult. Ethical considerations, including sustainable harvesting practices and animal welfare, are also increasingly shaping consumer acceptance and regulatory review.

What would it take for deer antler velvet to move from traditional remedy and speculative supplement to evidence-based therapeutic or functional ingredient? The review lays out a clear roadmap. First, researchers must establish defined compositional markers or fingerprints that correlate with biological activity, supported by validated analytical methods and bioassay-guided standardization. Second, rigorous pharmacokinetic and bioavailability studies are needed to determine which components, if any, reach systemic circulation in active form and at what doses. Third, well-powered randomized controlled trials evaluating clinically meaningful endpoints, rather than surrogate biomarkers, must be conducted with standardized formulations. Fourth, regulatory frameworks need harmonization grounded in reproducible quality control and transparent labeling. Technological innovations in extraction, stabilization, and delivery may help, but the authors caution that these must be accompanied by rigorous comparative evaluation rather than assumed improvements.

The broader lesson of the DAV story extends beyond a single ingredient. It illustrates a pattern familiar from many traditional natural products: a rich biochemical composition and compelling mechanistic plausibility that outpace the clinical evidence needed to justify health claims. Deer antler velvet genuinely contains molecules that regulate growth, redox balance, immune signaling, and tissue remodeling, and its intrinsic regenerative biology remains a fascinating model for studying angiogenesis, mineralization, and stem cell dynamics. But as the review’s authors conclude, the future of DAV in biomedical and nutraceutical applications will depend not on expanding the list of proposed benefits, but on deepening the validation behind each one. Until standardized compositions, pharmacokinetic clarity, and robust human trials arrive, consumers and clinicians alike should view this ancient remedy with informed, measured skepticism, appreciating its biological promise while recognizing how much rigorous science remains to be done.

Subject of Research: Bioactive composition, mechanisms, and translational challenges of deer antler velvet for biomedical and nutraceutical applications

Article Title: Deer antler velvet as a multifunctional natural resource for biomedical and nutraceutical applications

Article References: Lee, S.-J., Bak, S. G., Cheon, Y. J., Chandimali, N., & Bae, J. (2026). Deer antler velvet as a multifunctional natural resource for biomedical and nutraceutical applications. Food Science of Animal Resources, 46(1), Article 54. https://doi.org/10.1007/s44463-026-00070-z

Image Credits: AI Generated

DOI: 10.1007/s44463-026-00070-z

Keywords: deer antler velvet, IGF-1, growth factors, nutraceuticals, collagen, bioavailability, standardization, regenerative medicine, immunomodulation, antioxidant, functional foods, clinical trials

The study set out to answer a deceptively simple question: how do the growth hormone and insulin-like growth factor 1 pathways, often abbreviated as the GH/IGF-1 axis, behave in children whose insulin-producing cells have been destroyed by autoimmune attack? This axis is a cornerstone of pediatric physiology. The pituitary gland releases growth hormone in pulses, and the liver responds by producing IGF-1, which drives linear growth, muscle development, and cellular repair. Because insulin is a key permissive signal in this system, chronic insulin deficiency and the metabolic chaos of poorly controlled diabetes can theoretically dampen the entire axis. Testing that idea in a real pediatric population required careful measurement of hormones, growth parameters, and liver health in the same group of children.

The researchers enrolled 250 children with type 1 diabetes at a single center and performed a battery of assessments on each participant. These included standard anthropometric measurements such as height and body mass index, laboratory determination of growth hormone and IGF-1 levels measured by enzyme-linked immunosorbent assay, glycated hemoglobin, or HbA1c, as an index of average blood sugar control over the preceding months, and liver ultrasonography to screen for fatty liver disease. The team then applied multivariate logistic and linear regression models to identify which factors independently predicted MASLD and which predicted impaired linear growth. This statistical approach allowed them to disentangle the effects of age, sex, disease duration, glycemic control, and liver status from one another.

The results were sobering. The cohort’s mean HbA1c was 10.8 percent, a figure far above the recommended targets for children with diabetes and a clear indicator that, as a group, these children experienced prolonged periods of significant hyperglycemia. Against that backdrop, liver ultrasonography revealed MASLD in 36 percent of the participants, meaning roughly one in three children already carried fat deposits in the liver, a condition more commonly associated with obesity and insulin resistance than with type 1 diabetes. Equally striking was the hormonal picture: age-adjusted IGF-1 levels were reduced in 60 percent of the children, a majority of the cohort showing evidence of a blunted growth hormone axis.

When the researchers used regression analysis to identify independent predictors of MASLD, three factors emerged. Longer disease duration carried an odds ratio of 1.180, meaning each increment in the time a child had lived with diabetes increased the odds of fatty liver. HbA1c levels carried an odds ratio of 1.146, confirming that poorer glycemic control independently raised MASLD risk. Alanine aminotransferase, a liver enzyme released when hepatocytes are damaged or stressed, carried an odds ratio of 1.028, consistent with the biochemical signature of hepatic fat accumulation. Taken together, these predictors paint a coherent picture: the longer and more severely a child’s diabetes runs out of control, the more likely the liver is to accumulate fat.

Perhaps the most provocative finding concerned the relationship between fatty liver and the growth hormone axis. The presence of MASLD significantly increased the risk of reduced IGF-1 levels, with a relative risk of 1.841 and a 95 percent confidence interval of 1.113 to 3.044. Because that confidence interval excludes the value of 1, the association is statistically significant, and the magnitude suggests that children with fatty liver were nearly twice as likely to have low IGF-1 as those without it. The authors interpret this as evidence of significant hormonal dysregulation linked to insulin deficiency and metabolic decompensation. In other words, the liver, which is both the main source of circulating IGF-1 and the organ burdened by fat infiltration, may be failing on both fronts simultaneously in these children.

The story of linear growth proved more nuanced. On initial analysis, IGF-1 levels correlated with height, which would fit the textbook expectation that more growth factor means taller children. However, once the researchers adjusted for age and sex, that association lost statistical significance. What remained robust was disease duration, which stood out as a strong negative predictor of linear growth with a p-value of 0.000. This suggests that the cumulative burden of living with type 1 diabetes, rather than any single hormonal measurement, is what erodes a child’s growth trajectory over time. Chronic metabolic decompensation, recurrent insulin deficiency, and the hormonal disruptions documented in the study appear to accumulate, quietly constraining growth year after year.

Why should fatty liver disease appear in children with type 1 diabetes at all? The condition, now termed MASLD to reflect its metabolic underpinnings, is classically driven by insulin resistance, in which high circulating insulin levels push the liver to synthesize and store fat. Type 1 diabetes is defined by insulin deficiency rather than resistance, yet children with the disease are not immune to the metabolic syndrome, particularly when glycemic control is poor, body weight rises with exogenous insulin therapy, and fluctuating glucose levels create cycles of over- and under-insulinization. The high mean HbA1c in this cohort indicates that many of these children experienced exactly the kind of metabolic instability that can promote hepatic fat deposition even in the absence of endogenous insulin production.

The clinical implications are significant. First, the study suggests that liver ultrasonography and alanine aminotransferase monitoring deserve a place in routine pediatric diabetes care, since more than a third of these children had MASLD that could otherwise progress silently toward inflammation and fibrosis. Second, the high prevalence of reduced IGF-1 raises the question of whether growth monitoring and, where clinically indicated, assessment of the GH/IGF-1 axis should be integrated into follow-up for children with long-standing or poorly controlled diabetes. Third, the identification of HbA1c and disease duration as modifiable or trackable risk factors gives clinicians concrete targets: intensifying glycemic management early in the disease course may protect both the liver and the growth axis before irreversible damage accumulates.

The research, led by Feruzakhan Uvaidillaeva of the Kyrgyz-Russian Slavic University together with colleagues at the Kyrgyz State Medical Academy and the International Higher School of Medicine, was approved by the ethics committee of the Kyrgyz Medical Academy and conducted with informed consent from parents or legal guardians. As a single-center cross-sectional study, it captures a snapshot rather than a trajectory, so future longitudinal work will be needed to confirm whether fatty liver disease drives the hormonal changes, whether both are downstream of the same metabolic derangement, or whether the relationship runs in both directions. What the study establishes is that in children with type 1 diabetes, poor glycemic control and longer disease duration are the major factors associated with MASLD, and that MASLD itself travels with dysregulation of the GH/IGF-1 axis. For the millions of families managing type 1 diabetes worldwide, the message is clear: the disease’s reach extends well beyond blood sugar, into the liver and the very hormones that govern a child’s growth.

Subject of Research: GH/IGF-1 axis dysregulation and MASLD risk in children with type 1 diabetes

Article Title: Hormonal dysregulation of the GH/IGF-1 axis and its association with MASLD risk in children with type 1 diabetes

Article References: Uvaidillaeva, F., Tuhvatshin, R., Alisherova, A., Kniazeva, V., Omurkulova, B., Kim, T., & Toigonbaeva, B. (2026). Hormonal dysregulation of the GH/IGF-1 axis and its association with MASLD risk in children with type 1 diabetes. BMC Endocrine Disorders. https://doi.org/10.1186/s12902-026-02601-7

Image Credits: AI Generated

DOI: 10.1186/s12902-026-02601-7

Keywords: type 1 diabetes, MASLD, fatty liver disease, growth hormone, IGF-1, HbA1c, pediatric endocrinology, liver ultrasonography, glycemic control, linear growth, alanine aminotransferase, metabolic decompensation

Lymphatic vessels are best known as the body’s drainage network, collecting interstitial fluid, ferrying immune cells, and absorbing dietary fats. In most textbook accounts, they are supporting infrastructure rather than active participants in organ construction. The new study, published in the journal Genes & Development, challenges that view. Led by senior author Guillermo Oliver, the Thomas D. Spies Professor of Lymphatic Metabolism at Northwestern, the research demonstrates that cardiac lymphatic vessels send molecular signals to multiple types of heart cells, actively shaping how the growing heart regulates its own size.

The work builds directly on an earlier discovery from the Oliver laboratory, which showed that lymphatic vessels in the heart secrete a protein called Reelin. Reelin is famous in neuroscience, where it orchestrates the layered migration of neurons in the developing brain, but its role in the heart was a surprise. In that earlier work, the team found that Reelin promotes cardiac growth by stimulating the proliferation of cardiomyocytes, the contractile muscle cells that make up the bulk of the heart. When cardiomyocytes divide during embryonic development, the heart enlarges; when they stop dividing, as happens shortly after birth in mammals, that growth largely ceases.

The new study reveals that Reelin’s influence extends well beyond heart muscle. Using single-cell RNA sequencing, a technique that profiles gene expression in thousands of individual cells at once, combined with genetically engineered mouse models in which lymphatic-derived Reelin was eliminated, the researchers mapped a signaling pathway that connects the cardiac lymphatics to the epicardium, the thin layer of tissue that envelops the heart’s outer surface. The epicardium is far more than a protective membrane. During development it serves as a source of fibroblasts, coronary vascular cells, and growth factors, making it essential for normal cardiac morphogenesis.

What the team observed in mice lacking lymphatic-derived Reelin was striking. These hearts developed significant defects in the epicardium and lost specific populations of fibroblasts, the cells that build and maintain the heart’s structural scaffold. The investigators also documented a reduction in the number of epicardial cells expressing two critical cardiac factors: WT1, a transcription factor with well-established roles in epicardial biology and cardiac progenitor function, and insulin-like growth factor-1, or IGF-1, a potent growth factor that drives tissue expansion. In other words, removing a single lymphatic signal disrupted an entire regulatory network governing cardiac growth.

“We recently identified the cardiac lymphatic vasculature as an unexpected regulator of heart size during embryonic development,” Oliver said. “Here, by combining single-cell RNA sequencing with loss-of-function mouse models, we uncover another novel and unexpected critical regulatory network also participating in this process.” According to Oliver, the findings show that Reelin is not merely a muscle-cell proliferation signal but is essential for the maintenance and expansion of other cardiac cell types, including the epicardium and fibroblasts, and for sustaining the expression of WT1 and IGF-1, which together are responsible for the growth of the heart.

To test whether the mechanism holds in human tissue, the researchers turned to laboratory-grown human epicardioids, three-dimensional organoids that recapitulate key features of the developing heart’s outer lining. These mini-hearts, cultivated from human cells, allowed the team to probe Reelin’s effects in a controlled system that is more representative of human biology than mouse tissue alone. When the organoids were treated with Reelin protein, the expression of multiple epicardial markers increased, indicating that the protein promoted epicardial cell fate. This result supports the idea that Reelin directly influences epicardial maintenance during development and can even induce epicardial characteristics in the adult heart.

That last point carries significant implications for regenerative medicine. The mammalian heart loses most of its regenerative ability shortly after birth, and the epicardium, so active during embryogenesis, becomes largely dormant in the adult. Yet this dormant layer retains latent developmental programs that can be partially reawakened after injury, such as a heart attack, when the epicardium thickens and re-expresses genes like WT1. The Northwestern findings suggest that the beneficial effects of lymphatic vessels during adult cardiac injury may be partly mediated by Reelin reactivating the dormant epicardium, potentially leading to more efficient repair. If researchers could one day harness or mimic that signal, they might enhance the heart’s limited self-repair capacity after a myocardial infarction, the leading cause of death worldwide.

Timing appears to be everything. Oliver noted that Reelin expression in cardiac lymphatics declines progressively after birth and becomes nearly undetectable by day seven of life in mice. That postnatal decrease coincides precisely with the window in which newborn mice lose their ability to regenerate heart tissue, a phenomenon first described in landmark studies showing that a one-day-old mouse can fully repair its heart after surgical injury, while a seven-day-old mouse cannot. “This postnatal decrease coincides with the cessation of cardiac regeneration in newborn mice, suggesting that loss of Reelin may contribute to the arrest of these processes,” Oliver said. The correlation does not prove causation, but it provides a compelling lead for scientists trying to understand why the regenerative capacity of the heart switches off so early in life.

Beyond regeneration, the work may illuminate the origins of congenital heart defects, which affect roughly one percent of live births and often involve faults in the very cell types and signaling pathways the study identifies. If lymphatic-derived signals are required for proper epicardial maintenance, fibroblast development, and growth factor expression, then disruptions in cardiac lymphatic development could plausibly contribute to structural heart malformations, a hypothesis the authors suggest is worth investigating in future work.

Oliver and his colleagues have also proposed a broader and provocative conceptual model: that lymphatic vessels may function as organ-wide monitoring systems that help determine when growth is complete. As lymphatics grow into a developing organ, they are uniquely positioned to sample functional features of the tissue around them, including interstitial fluid pressure, the accumulation of metabolic waste, and tissue stiffness, all of which change as an organ matures. “What we propose is that it’s possible that lymphatics function as organ-level quality control systems,” Oliver said. In this view, the vessels continuously assess the organ’s condition and relay instructions: keep growing, keep proliferating, until the tissue reaches an appropriate state, and then stop.

If that model proves correct across organ systems, it would reframe the lymphatic vasculature from a passive drainage network into an active, instructive component of organogenesis, with Reelin as one of its molecular messengers. It would also connect two fields that have historically developed in parallel, lymphatic biology and cardiac developmental biology, around a shared question of size control. The technical achievements underpinning the study, from single-cell transcriptomics that resolved the cross-talk between lymphatic endothelial cells, epicardial cells, and fibroblasts, to the generation of human epicardioids that allowed direct functional testing, illustrate how modern tools are enabling biologists to dissect these multicellular conversations with unprecedented precision.

Much remains to be determined. The study was conducted in mice and in lab-grown organoids, and translating the findings to human therapy will require years of additional research, including work to establish whether Reelin signaling can be safely and effectively modulated in the injured adult heart. Still, the central message is clear and conceptually striking: the heart’s blueprint for growth is not written in muscle cells alone. It is co-authored by the lymphatic vessels threading through the organ, which whisper instructions to the epicardium, sustain the fibroblasts that build its framework, and keep the growth factors flowing until the job is done. Understanding that conversation, the Northwestern team argues, could ultimately give science new insight into how the heart responds to and repairs itself after a heart attack, turning a developmental curiosity into a potential therapeutic frontier.

Subject of Research: The role of lymphatic-derived Reelin signaling in regulating epicardial maintenance and cardiac growth during heart development

Article Title: Study reveals a new way the developing heart controls its growth

Article References: Study reveals a new way the developing heart controls its growth. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: cardiac lymphatics, Reelin, epicardium, heart development, cardiomyocyte proliferation, fibroblasts, WT1, IGF-1, organoids, regeneration, congenital heart defects, single-cell RNA sequencing